Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis
Diseases,
Год журнала:
2024,
Номер
12(3), С. 41 - 41
Опубликована: Фев. 21, 2024
Plasma
collected
from
people
recovered
COVID-19
(COVID-19
convalescent
plasma,
CCP)
was
the
first
antibody-based
therapy
employed
to
fight
pandemic.
CCP
was,
however,
often
in
combination
with
other
drugs,
such
as
antiviral
remdesivir
and
glucocorticoids.
The
possible
effect
of
interaction
has
never
been
investigated
systematically.
To
assess
safety
efficacy
combined
agents
for
treatment
patients
hospitalized
COVID-19,
a
systematic
literature
search
using
appropriate
Medical
Subject
Heading
(MeSH)
terms
performed
through
PubMed,
EMBASE,
Cochrane
central,
medRxiv
bioRxiv.
main
outcomes
considered
were
mortality
treatments
versus
alone.
This
review
carried
out
accordance
methodology
including
risk
bias
assessment
grading
quality
evidence.
Measure
ratio
(RR)
together
95%
confidence
intervals
(CIs).
A
total
11
studies
(8
randomized
controlled
trials
[RCTs]
3
observational)
included
review,
4
6
corticosteroids,
all
involving
patients.
One
RCT
reported
information
on
both
steroids
use
CCP.
associated
significantly
reduced
death
(RR
0.74;
CI
0.56–0.97;
p
=
0.03;
moderate
certainty
evidence),
while
did
not
modify
0.72;
0.34–1.51;
0.38;
very
low
evidence).
Not
enough
data
retrieved
form
analysis.
current
evidence
suggests
potential
beneficial
plus
compared
alone
No
significant
clinical
found
between
steroids.
Язык: Английский
Clinical efficacy of SARS‐CoV‐2 Omicron‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency
Journal of Medical Virology,
Год журнала:
2024,
Номер
96(6)
Опубликована: Июнь 1, 2024
Immunocompromised
individuals
are
at
significantly
elevated
risk
for
severe
courses
of
coronavirus
disease
2019
(COVID-19).
In
addition
to
vaccination,
acute
respiratory
syndrome
2
(SARS-CoV-2)
neutralizing
antibodies
(nAbs)
have
been
applied
throughout
the
pandemic,
with
time
treatment
onset
and
potency
against
currently
prevailing
virus
variant
identified
as
relevant
factors
medical
benefit.
Using
data
from
European
Society
Immunodeficiencies
(ESID)
registry,
present
study
evaluated
COVID-19
cases
in
three
groups
patients
inborn
errors
immunity
(IEI;
981
agammaglobulinemia
on
immunoglobulin
replacement
therapy
(IGRT);
8960
non-agammaglobulinemia
IGRT;
14
428
without
IGRT),
capacity
1100
lots
SARS-CoV-2
("Wuhan"
Omicron
strains),
3
years.
From
first
(2020/2021)
second
(2021/2022)
cold
season,
i.e.,
during
drift
more
contagious
variants,
an
increase
case
numbers
was
recorded
that
comparable
(~2-
3-fold)
all
groups.
During
same
period,
showed
a
profound
nAb
archetypal
strain,
yet
only
low
levels
nAbs.
Notably,
shortly
before
third
(2022/2023)
Omicron-neutralizing
released
had
plateaued
high
levels.
dropped
markedly.
While
~6-fold
reduction
IGRT
IEI
not
receiving
IGRT,
decline
~30-fold
group
IGRT.
These
findings
suggest
substantial
COVID-19-protective
effect
least
distinct
antibody-deficient
patients.
Язык: Английский